Treating Heart Disease Behind Sudden Death in Young People | David Elsley - Cardiol Therapeutics

Register here for The 2026 Rule Symposium on Natural Resource Investing:
LINK HERE: https://cvent.me/XOqdLa?via=TheDeepDive.ca

#cardio #biotechnology #médecine #stockmarket #finance

In this conversation with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we discuss the company’s progress in inflammatory heart disease, including momentum in the Phase 3 MAVERIC trial for recurrent pericarditis, new data from the Phase 2 ARCHER program in myocarditis, and why the latest results could have implications far beyond rare disease. David explains what makes these conditions so difficult to treat, why the current standard of care remains limited, and how Cardiol is positioning both its lead oral therapy and its next-stage once-monthly heart failure asset for major value-creating milestones ahead.

What makes this discussion stand out is that it is not just about one trial update. David lays out how the company is moving from rare cardiac disease toward much larger commercial opportunities, why the recent myocarditis data matters scientifically, and how Cardiol’s balance sheet now supports key catalysts through Phase 3 readout, regulatory work, and the advance of CRD38 into clinical development. If you value real conversations that break down biotech stories without the usual noise, subscribe to the channel and share this with someone else following the market. That support helps us keep bringing on guests like this and asking the questions that matter.



Catch our full suite of content below:
Website: https://thedeepdive.ca/
Twitter: https://twitter.com/TheDeepDive_ca
Facebook: https://www.facebook.com/TheDeepDive.ca/
Instagram: https://www.instagram.com/the.deep.dive/
LinkedIn: https://www.linkedin.com/company/the-...

====================================================================

Looking for better insights on the markets? The Deep Dive Spotlights is providing exclusive industry insights from executives, insiders, technicians, specialists and more.

We're upgrading our Canadian small cap coverage from written to visual, hitting investors with a double dose of market insights to provide a special look into just what's happening in the Canadian public markets.
=================================================================
TheDeepDive.ca Team

Writers: Jordan Lutz & Steve Hyland
Producer: Chriz Rayos
Host: Steve Hyland
Post Production Head: Oveja Rayos

=================================================================



Disclaimer:
Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security. The Deep Dive and its affiliates hold no licenses.
00:00 Introduction
00:33 The Heart Drug Story Taking Shape
02:31 The Data That Got Attention
04:25 Why the Trial Is Gaining Speed
05:55 The Drug With the Bigger Market
08:10 The Treatment Gap No One Has Solved
10:05 Balance Sheet Strength and Partnering Leverage
11:39 What Has to Happen Next